AI Drug Developer for Gut Microbiota

Recently, the 111th China National Sugar and Alcohol Commodities Fair opened at the Shenzhen International Convention and Exhibition Center. This year's fair will invite over 4,200 industry manufacturers from more than 40 countries and regions, as well as 200,000 professional domestic and international visitors, to engage in trading and exchanges, providing an international exhibition platform for the food and alcohol industry that integrates display, trading, communication, and cooperation.
From October 24 to 28, the hotel exhibition of the Sugar and Wine Fair kicked off first,Xbiome Partners with Probiotics Collaborator Shenzhen Health Express Dairy Co., Ltd. (hereinafter referred to as "Health Express") to Set Up Booth at Greater China Sheraton Hotel; During the Event, Health Express Launched Five New Probiotics Products Jointly Developed by Both Parties。Xbiome Co-Founder and CEO Dr. Tan Yan, along with Health Express CEO Mr. Lin Yu Li, personally attended the exhibition to explain the new products of Health Express and Xbiome's collaboration model in empowering food and health enterprises through probiotic research and development.



Health Express launched five probiotic solid beverages: "Xiaoran Jun" for weight management, "Qi Ning Jun" for mental regulation, "Changyang Jun" for feminine care, "Jianbu Jun" for bone health, and "Huanzhuo Jun" for late-night socializing. At the exhibition, Health Express divided its booth into five sections to introduce the features of these products in detail. To allow consumers to experience the products better, a free tasting session was set up at the venue, attracting many visitors to taste and explore.
The probiotic products launched this time are all developed based on Xbiome's self-developed patented functional strains. They have undergone rigorous processes including functional mining, safety assessment, efficacy evaluation, formulation, and process development, featuring novel and unique functions with excellent data. Both parties hope that through this exhibition, consumers will be inspired to enhance their awareness of the diversity, scientific basis, and importance of probiotics to health.

Staff of the Health Express introduced that the company will continue to uphold the concept of scientific evidence, strengthen cooperation and exchange with the biomedicine community both in China and internationally, continuously enhance the technological content and competitiveness of its products, provide consumers with higher-quality probiotic products and services, and make greater contributions to the cause of human health. Dr. Tan Yan said that Xbiome will utilize an AI microbiome research and industrial transformation platform, which is also used for rigorous microbial drug studies, to continuously explore beneficial functional strains for the human body.Provide probiotic R&D solutions based on scientific evidence research to support the development of industry partners.
During the hotel exhibition, industry partners and renowned investors, including Huang Maozhan, Chairman of the Board of Shenzhen Zhongrun Group, Wen Shuhao, Chairman of the Board of XtalPi, Wei Guoxing, Partner of Tiantu Investment, and Liu Chong, Founding Partner of Yiyi Capital, came to the booth to show their support. The attending guests gained an in-depth understanding of the new products from Health Express Dairy and praised the concept of Health Express creating "probiotic strains more suitable for the Chinese people's physique."

About Health Express
Shenzhen Health Express Dairy Co., Ltd., formerly known as "Shenzhen Xizhikang Beverage Co., Ltd.," was registered and established in 1998. In 2003, it reached a strategic cooperation with Walmart, and its lactic acid bacteria beverage products were available in Walmart supermarkets across China. In 2012, the company acquired the "Health Express AD Calcium Milk" series from Danone and established "Shenzhen Health Express Dairy Co., Ltd." in 2013. In 2024, Health Express reached a strategic cooperation with Yonghui Supermarket, and its products became bestsellers in stores nationwide across China.
About Xbiome
Xbiome Co. Ltd., founded in 2017, owns a leading AI microbiome research and industrial transformation platform, strategically focusing on FMT, drug discovery, and probiotics. In drug discovery, the team has completed layouts in fields such as oncology, digestive diseases, immune-related diseases, and urological diseases, with four pipelines entering clinical stages, two of which are in Phase II clinical trials. Regarding FMT, Xbiome has collaborated with nearly 20 well-known tertiary hospitals in China, including Peking University Cancer Hospital and Peking Union Medical College Hospital, to conduct gut microbiome clinical research across various indications. Additionally, they have developed the AI-FMT personalized precision treatment project for gut microbiota, targeting the broader health market to benefit patients with chronic diseases and sub-health populations. In the field of probiotics, Xbiome has successfully completed commercial collaborations and transformations with several top domestic and international health companies and is continuously advancing the development of proprietary strains.
-End-
Note: The content of this article is based on the news reports from Shenzhen Special Zone Daily, Shenzhen Commercial Daily, Shenzhen Evening News, and Shenzhen News Network.